Eiger BioPharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eiger BioPharmaceuticals, Inc.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed
The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Celladon Corporation